UNLABELLED: Chemokines critically control the infiltration of immune cells upon liver injury, thereby promoting hepatic inflammation and fibrosis. The chemokine receptor CCR8 can affect trafficking of monocytes/macrophages, monocyte-derived dendritic cells (DCs) and T-helper cell (Th) subsets, but its role in liver diseases is currently unknown. To investigate the functional role of CCR8 in liver diseases, ccr8(-/-) and wild-type (WT) mice were subjected to chronic experimental injury models of carbon tetrachloride (CCl(4) ) administration and surgical bile duct ligation (BDL). CCR8 was strongly up-regulated in the injured liver. Ccr8(-/-) mice displayed attenuated liver damage (e.g., ALT, histology, and TUNEL) compared to WT mice and were also protected from liver fibrosis in two independent injury models. Flow cytometry revealed reduced infiltrates of liver macrophages, neutrophils and natural killer cells, whereas hepatic CD4(+) T cells increased. The main CCR8-expressing cells in the liver were hepatic macrophages, and CCR8 was functionally necessary for CCL1-directed migration of inflammatory but not for nonclassical monocytes into the liver. Moreover, the phenotype of liver macrophages from injured ccr8(-/-) animals was altered with increased expression of DC markers and enhanced expression of T-cell-attracting chemokine macrophage inflammatory protein 1-alpha (MIP-1α/CCL3). Correspondingly, hepatic CD4(+) T cells showed increased Th1 polarization and reduced Th2 cells in CCR8-deficient animals. Liver fibrosis progression, but also subsequent T-cell alterations, could be restored by adoptively transferring CCR8-expressing monocytes/macrophages into ccr8(-/-) mice during experimental injury. CONCLUSIONS: CCR8 critically mediates hepatic macrophage recruitment upon injury, which subsequently shapes the inflammatory response in the injured liver, affecting macrophage/DC and Th differentiation. CCR8 deficiency protects the liver against injury, ameliorating initial inflammatory responses and hepatic fibrogenesis. Inhibition of CCR8 or its ligand, CCL1, might represent a successful therapeutic target to limit liver inflammation and fibrosis progression.
UNLABELLED: Chemokines critically control the infiltration of immune cells upon liver injury, thereby promoting hepatic inflammation and fibrosis. The chemokine receptor CCR8 can affect trafficking of monocytes/macrophages, monocyte-derived dendritic cells (DCs) and T-helper cell (Th) subsets, but its role in liver diseases is currently unknown. To investigate the functional role of CCR8 in liver diseases, ccr8(-/-) and wild-type (WT) mice were subjected to chronic experimental injury models of carbon tetrachloride (CCl(4) ) administration and surgical bile duct ligation (BDL). CCR8 was strongly up-regulated in the injured liver. Ccr8(-/-) mice displayed attenuated liver damage (e.g., ALT, histology, and TUNEL) compared to WT mice and were also protected from liver fibrosis in two independent injury models. Flow cytometry revealed reduced infiltrates of liver macrophages, neutrophils and natural killer cells, whereas hepatic CD4(+) T cells increased. The main CCR8-expressing cells in the liver were hepatic macrophages, and CCR8 was functionally necessary for CCL1-directed migration of inflammatory but not for nonclassical monocytes into the liver. Moreover, the phenotype of liver macrophages from injured ccr8(-/-) animals was altered with increased expression of DC markers and enhanced expression of T-cell-attracting chemokine macrophage inflammatory protein 1-alpha (MIP-1α/CCL3). Correspondingly, hepatic CD4(+) T cells showed increased Th1 polarization and reduced Th2 cells in CCR8-deficient animals. Liver fibrosis progression, but also subsequent T-cell alterations, could be restored by adoptively transferring CCR8-expressing monocytes/macrophages into ccr8(-/-) mice during experimental injury. CONCLUSIONS:CCR8 critically mediates hepatic macrophage recruitment upon injury, which subsequently shapes the inflammatory response in the injured liver, affecting macrophage/DC and Th differentiation. CCR8 deficiency protects the liver against injury, ameliorating initial inflammatory responses and hepatic fibrogenesis. Inhibition of CCR8 or its ligand, CCL1, might represent a successful therapeutic target to limit liver inflammation and fibrosis progression.
Authors: Karlin Raja Karlmark; Henning W Zimmermann; Christoph Roderburg; Nikolaus Gassler; Hermann E Wasmuth; Tom Luedde; Christian Trautwein; Frank Tacke Journal: Hepatology Date: 2010-11 Impact factor: 17.425
Authors: Igor Shamovsky; Chris de Graaf; Lisa Alderin; Malena Bengtsson; Håkan Bladh; Lena Börjesson; Stephen Connolly; Hazel J Dyke; Marco van den Heuvel; Henrik Johansson; Bo-Göran Josefsson; Anna Kristoffersson; Tero Linnanen; Annea Lisius; Roope Männikkö; Bo Nordén; Steve Price; Lena Ripa; Didier Rognan; Alexander Rosendahl; Marco Skrinjar; Klaus Urbahns Journal: J Med Chem Date: 2009-12-10 Impact factor: 7.446
Authors: Tom Bosschaerts; Martin Guilliams; Benoît Stijlemans; Yannick Morias; Daniel Engel; Frank Tacke; Michel Hérin; Patrick De Baetselier; Alain Beschin Journal: PLoS Pathog Date: 2010-08-12 Impact factor: 6.823
Authors: Sebastian Seidler; Henning W Zimmermann; Matthias Bartneck; Christian Trautwein; Frank Tacke Journal: BMC Immunol Date: 2010-06-21 Impact factor: 3.615
Authors: H L Tiffany; L L Lautens; J L Gao; J Pease; M Locati; C Combadiere; W Modi; T I Bonner; P M Murphy Journal: J Exp Med Date: 1997-07-07 Impact factor: 14.307
Authors: Mili Mandal; Carol R Gardner; Richard Sun; Hyejeong Choi; Sonali Lad; Vladimir Mishin; Jeffrey D Laskin; Debra L Laskin Journal: Toxicol Appl Pharmacol Date: 2016-05-07 Impact factor: 4.219
Authors: Silke R Brix; Gesa Stege; Erik Disteldorf; Elion Hoxha; Christian Krebs; Sonja Krohn; Benjamin Otto; Kristin Klätschke; Elisabeth Herden; Felix Heymann; Sergio A Lira; Frank Tacke; Gunter Wolf; Martin Busch; Wolfram J Jabs; Fedai Özcan; Frieder Keller; Joachim Beige; Karl Wagner; Udo Helmchen; Mercedes Noriega; Thorsten Wiech; Ulf Panzer; Rolf A K Stahl Journal: J Am Soc Nephrol Date: 2015-03-11 Impact factor: 10.121